AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01271010
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants received cyclophosphamide 250 mg/m\^2 IV or 250 mg/m\^2 orally on Days 1-3 of each cycle.
Trial: NCT03062280
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Modified release hydrocortisone
Trial: NCT02920528
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline
Trial: NCT01879462
Drug: GSK2878175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Round tablets (5.0mg) given once daily single and repeated (to 7 days), Oral dose.
Trial: NCT01879462
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visually matching GSK2878175
Trial: NCT00426816
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match SB-649868
Trial: NCT00116701
Drug: Aranesp®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03892668
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An equal volume of normal saline syringe in a double blinded manner will be intravenously administered to the Oxytocin group 30 min before surgery and will be followed by 500 ml saline infusion during the operation
Trial: NCT04622891
Drug: Clarithromycin 500mg
RxNorm normalized name: CLARITHROMYCIN 500MG TAB
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: clarithromycin 500
Trial: NCT04622891
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: azithromycin group
Trial: NCT04622891
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control group
Trial: NCT03587701
Drug: Placebo injection (Period 1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pre-filled matching placebo injections will be provided and will be self-administered by patients daily during first 42 days of treatment (Period 1)
Trial: NCT03587701
Drug: Placebo injection (Period 2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pre-filled matching placebo injections will be provided and will be self-administered by patients daily during next 42 days of treatment (Period 2)
Trial: NCT00388388
Drug: losartan, hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan, 50-100 mg per day, once a day, for 6 months. Hydrochlorothiazide, 12.5-25 mg per day, once a day, for 6 months.
Trial: NCT00837265
Drug: Chemotherapy Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The chemotherapy regimen consisting of doxorubicin 60 mg/square meter (m\^2) and docetaxel 75 mg/m\^2 will be administered sequentially by intravenous (IV) infusion on Day 1 of treatment for up to four 21-day cycles.
Trial: NCT00925106
Drug: Test formulation D1
RxNorm normalized name: PHOSPHOLIPASE D1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose 150 mg celecoxib as formulation D1
Trial: NCT00925106
Drug: Test formulation D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose 150 mg celecoxib as formulation D3
Trial: NCT01601106
Drug: liposomal prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two weekly dosages with 150 mg.
Trial: NCT01601106
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03286829
Drug: Tesomet High dose in fed condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
Trial: NCT01942668
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01942668
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03215758
Drug: QAW039
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QAW039 once daily
Trial: NCT03215758
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily
Trial: NCT00760435
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (same volume as active drug)
Trial: NCT02182206
Drug: BIBF 1120
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01540630
Drug: CNV1014802
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNV1014802 150mg tid for 28 days. Dose may be increased to 350mg bid following interim evaluation of efficacy.
Trial: NCT01540630
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blind placebo comparator for 28 days.
Trial: NCT00538967
Drug: doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 weeks once daily
Trial: NCT03096795
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single dose of placebo matched to MEDI3506 subcutaneously or intravenously in Part 1. Participants with COPD will receive 3 administration of placebo matched to MEDI3506 subcutaneously two weeks apart over a 4-week dosing period in Part 2. Healthy Japanese participants will receive a single dose of placebo matched to MEDI3506 intravenously in Part 3.
Trial: NCT02813096
Drug: folfox4 chemotherapy regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folfox regimen:Oxaliplatin 85 mg/m2 in 250 mL 5% glucose solution, IVD (administered as 2-hour infusion) on day 1;leucovorin 200 mg/m2 in 100 mL 0.9% NaCl solution, IVD (administered as 2-hour infusion) on days 1 and 2; 400 mg/m2 5-FU in 20mL 0.9% NaCl solution, IV(administered as follow leucovorin); then 600 mg/m2 5-FU in 100 mL 0.9% NaCl solution (administered as 22-hour continuous infusion) on days 1 and 2 of each 14 days cycle.~Number of cycles: 4 cycles, or until progression or unacceptable toxicity develops.
Trial: NCT03257202
Drug: Clindamycin 1% Gel
RxNorm normalized name: BENZOYL PRX 5%/CLINDAMYCIN 1% GEL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical clindamycin
Trial: NCT03257202
Drug: BenzaClin 5%-1% Topical Gel
RxNorm normalized name: BenzaClin 5%-1% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical clindamycin and benzoyl peroxide together
Trial: NCT02642393
Drug: Inosine
RxNorm normalized name: Inosine
DrugBank: Inosine (DB04335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: capsules containing 500 mg of inosine
Trial: NCT02642393
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules containing \~500 mg of lactose and appearing indistinguishable from inosine capsules
Trial: NCT04147390
Drug: prescribe mycophenolate mofetil(MMF)
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MMF orally 1 g twice daily for the first 6 months and then 1 g daily for the next 6 months
Trial: NCT00648427
Drug: Paxil CR™ Tablets 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25mg, single dose fasting
Trial: NCT01463696
Drug: MK-8242
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg, 100 mg and 150 mg capsules
Trial: NCT03072394
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local skin anesthesia during radial coronary artery catheterization by EMLA anesthetic ointment
Trial: NCT00222235
Drug: glycine
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00222235
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03770325
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets, prepared with the same appearance, for 12 weeks
Trial: NCT00425698
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 3x IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
Trial: NCT02982434
Drug: 0.9% normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00853242
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00853242
Drug: Genz-644470
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00434447
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01164891
Drug: RO5185426
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous oral dosing b.i.d. , on Day 15 a C isotope labeled dose will be administered
Trial: NCT03985943
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01823159
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral administration of a tablet
Trial: NCT01471379
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive pill, identical in shape, size, and appearance to active drug, PO, BID.
Trial: NCT00262886
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01357538
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: corresponding vehicle, eye ointment applied to the eye lid
Trial: NCT00632827
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cancer medication that interferes with the growth and spread of cancer cells in the body
Trial: NCT00632827
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin is used to prevent harmful effects of methotrexate when methotrexate is used to treat certain types of cancer.
Trial: NCT00632827
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate is a chemotherapy medication used to treat cancer
Trial: NCT00632827
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin Hydrochloride is a chemotherapy medication used to treat cancer
Trial: NCT04571424
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm
Trial: NCT01520701
Drug: Ialuset®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to receive reference of the application of cervical Ialuset® on skin throughout the treatment period (the first day to last day of radiotherapy).
Trial: NCT00086801
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: given IV
Trial: NCT04295681
Drug: MMH-MAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT04295681
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT04521686
Drug: LY3410738
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral LY3410738
Trial: NCT01262638
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily for 12 weeks
Trial: NCT03449940
Drug: Diclofenac Sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral Diclofenac Sodium 50mg tablet is prescribed to be taken as needed up to a maximum of three times daily until the penis is repaired.
Trial: NCT01071252
Drug: AIN457
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01071252
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00152828
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03578575
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is a very low dose Danggui Buxue Tang powder.
Trial: NCT04181593
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mineral oil Softgels
Trial: NCT05319899
Drug: ALXN1840
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALXN1840 (60 milligrams) was administered orally as non-coated capsules at Hour 0 on Day 1.
Trial: NCT02890953
Drug: Pneumostem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: direct intracerebroventricular injection of mesenchymal stem cells via ventricular tap
Trial: NCT02890953
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: direct intracerebroventricular injection of normal saline via ventricular tap
Trial: NCT01661777
Drug: Nasal steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01661777
Drug: Diuretic
RxNorm normalized name: Diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00767663
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo twice daily, minimal three days pretreatment
Trial: NCT00053677
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For subjects who were randomly assigned to placebo.
Trial: NCT01360749
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo dose: 2 g for 10 cm2.
Trial: NCT03759886
Drug: Paromomycin Sulfate Powder
RxNorm normalized name: Paromomycin Sulfate
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients receive Paromomycin and Metronidazole the day prior to colorectal surgery after mechanical bowel preparation
Trial: NCT01723618
Drug: CRD007
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01478126
Drug: N(2)-L-Alanine L-Glutamine dipeptide
RxNorm normalized name: N-ethyl-L-glutamine
DrugBank: Theanine (DB12444)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of glutamine in total dose of 2 g/kg/day (rate=2\*weight/24 ml/h). Infusion starts in operating room and ends next day after the surgery.
Trial: NCT00094861
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04473950
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An IM injection of 0.9% normal saline will be given.
Trial: NCT01958645
Drug: MEDI8111
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI8111 lyophilisate for solution for infusion
Trial: NCT03183128
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be identical to the investigational product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline(0.9%).
Trial: NCT03486873
Drug: Standard of Care (SOC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion or oral tablets
Trial: NCT03486873
Drug: MK-4280
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Infusion
Trial: NCT02351063
Drug: Changes of heart failure medications
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Changes in dosage of existing medications or introduction of new medications to improve heart failure condition.
Trial: NCT02547038
Drug: (panto+amox+clar+metr)+(panto+amox)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
Trial: NCT00964665
Drug: Pegasys®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01478126
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 0,9% solution of NaCl, rate=2\*weight/24. Infusion starts in operating room and ends next day after the surgery.
Trial: NCT04314193
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral methotrexate (15 mg weekly to be increased to 25 mg weekly) for 24 weeks.
Trial: NCT00644293
Drug: azithromycin (Zithromax)
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: azithromycin 500 mg tablet by mouth once daily for 3 days
Trial: NCT00644293
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03206463
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will have 1/3 chance of receiving the inhaled placebo condition administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing. The placebo condition will include no active cannabinoids.
Trial: NCT00802360
Drug: Progestrone vaginal insert
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg progesterone vaginal insert 2 or 3 times daily (BID or TID) (start on the day after oocyte retrieval) until 10 weeks gestation or confirmation of negative pregnancy test.
Trial: NCT00644293
Drug: azithromycin SR
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: azithromycin SR 2.0 g by mouth as an oral slurry for 1 dose
Trial: NCT04513951
Drug: 5Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: phase II
Trial: NCT04513951
Drug: L-leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: phase II
Trial: NCT04546009
Drug: LHRH Agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only premenopausal/perimenopausal and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
Trial: NCT04047875
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identically appearing placebo to Primolut-Nor®, 1 pill per day until 2 consecutive days without bleeding/spotting
Trial: NCT02882789
Drug: LCB01-0371
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort1 \& 3: Placebo-controlled, Single ascending dose administration
Trial: NCT02882789
Drug: LCB01-0371 400mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 2: Crossover designed administration
Trial: NCT04379479
Drug: Placebo oral
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01511614
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine deprived
Trial: NCT01511614
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active comparator to varenicline
Trial: NCT00501592
Drug: INT-747
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg by mouth once daily, 50 mg by mouth once daily
Trial: NCT00501592
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00954629
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical solution to be applied twice daily for 26 weeks. Dosage up till 4ml per application.
Trial: NCT03350035
Drug: IV Placebo, non-active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT01900171
Drug: QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01900171
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contains magnesium stearate, silica dental type, anhydrous lactose
Trial: NCT04187508
Drug: AZD8154 nebulizer suspension, 20 mg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive AZD8154 from Day 1 to Day 10 (10 consecutive days) by using nebulizer and dosimeter system as inhaled dosing and delivered dose will be 3mg.
Trial: NCT04187508
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive AZD8154 matching placebo (placebo nebulizer suspension, glucose solution for infusion 50 mg/mL) QD from Day 1 to Day 10 (10 consecutive days) by using nebulizer and dosimeter system as inhaled dosing.
Trial: NCT00562497
Drug: Prochymal®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prochymal® intravenous infusion.
Trial: NCT00365105
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4 mg of Zoledronic acid intravenously once a month until the study doctor thinks it is in their best interest to stop.
Trial: NCT04299503
Drug: Placebo Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For every 10% of scalp affected, approximately ½ finger tip of study drug will be needed to cover the area with a thin layer. After the first application at baseline, the tubes will be weighed to determine the dose needed to cover the affected area. This will be the subject's target dose throughout the study
Trial: NCT04054479
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive 0.1ml/kg normal saline(up to 5ml) after anesthesia intubation.